UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cardiovascular effects of approved drugs for rheumatoid arthritis

Nature reviews. Rheumatology, 2021-05, Vol.17 (5), p.270-290

2021

Volltextzugriff (PDF)

Metabolic Induction of Trained Immunity through the Mevalonate Pathway

Cell, 2018-01, Vol.172 (1-2), p.135-146.e9

2018

Volltextzugriff (PDF)

Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study

Annals of the rheumatic diseases, 2017-10, Vol.76 (10), p.1693-1699

2017

Volltextzugriff (PDF)

The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients

Annals of the rheumatic diseases, 2015-06, Vol.74 (6), p.998-1003

2015

Volltextzugriff (PDF)

Rheumatoid Arthritis Disadvantages Younger Patients for Cardiovascular Diseases: A Meta-Analysis

PloS one, 2016-06, Vol.11 (6), p.e0157360-e0157360

2016

Volltextzugriff (PDF)

Younger age and female gender are determinants of underestimated cardiovascular risk in rheumatoid arthritis patients: a prospective cohort study

Arthritis research & therapy, 2021-01, Vol.23 (1), p.2-2, Article 2

2021

Volltextzugriff (PDF)

Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial

Rheumatic & musculoskeletal diseases open, 2021-03, Vol.7 (1), p.e001591

2021

Volltextzugriff (PDF)

Intramuscular methylprednisolone administration in hand osteoarthritis patients: a feasibility study to inform a randomized controlled trial

Therapeutic advances in musculoskeletal disease, 2024-01, Vol.16, p.1759720X241253974-1759720X241253974

2024

Volltextzugriff (PDF)

Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals

Mediators of Inflammation, 2012-01, Vol.2012 (2012), p.591-599-165

2012

Volltextzugriff (PDF)

Cardiovascular risk management in rheumatoid arthritis: challenges ahead

Rheumatology (Oxford, England), 2017-09, Vol.56 (9), p.1443-1444

Popa, Calin D

2017

Volltextzugriff (PDF)

Does Adding Single‐Nucleotide Polymorphisms to Risk Algorithms Improve Cardiovascular Disease Risk Prediction in Rheumatoid Arthritis? An Internal and External Validation of a Clinical Risk Score

Arthritis care & research (2010), 2024-10, Vol.76 (10), p.1419-1426

2024

Volltextzugriff (PDF)

Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events

Expert review of clinical immunology, 2022-03, Vol.18 (3), p.233-244

2022

Volltextzugriff (PDF)

Shared decision making in routine clinical care of patients with rheumatoid arthritis: an assessment of audio-recorded consultations

Annals of the rheumatic diseases, 2020-02, Vol.79 (2), p.170-175

2020

Volltextzugriff (PDF)

Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population

Rheumatology (Oxford, England), 2024-08, Vol.63 (8), p.2142-2146

2024

Volltextzugriff (PDF)

Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases

Atherosclerosis, 2017-09, Vol.264, p.83-91

2017

Volltextzugriff (PDF)

Association of Low-Dose Colchicine With Incidence of Knee and Hip Replacements : Exploratory Analyses From a Randomized, Controlled, Double-Blind Trial

Annals of internal medicine, 2023-06, Vol.176 (6), p.737-742

2023

Volltextzugriff (PDF)

The Use of Captopril in Rheumatoid Arthritis: Combining Treatment Targets

Canadian journal of cardiology, 2013-05, Vol.29 (5), p.639.e13-639.e13

2013

Volltextzugriff (PDF)

Interventions to support shared decision making for medication therapy in long term conditions: A systematic review

Patient education and counseling, 2020-02, Vol.103 (2), p.254-265

2020

Volltextzugriff (PDF)

Diagnostic parameters of cellular tests for Lyme borreliosis in Europe (VICTORY study): a case-control study

The Lancet infectious diseases, 2022-09, Vol.22 (9), p.1388-1396

2022

Volltextzugriff (PDF)

Atherosclerosis in Rheumatoid Arthritis

Mediators of Inflammation, 2012-01, Vol.2012, p.921-922

2012

Volltextzugriff (PDF)

Transgenic mice expressing human IL-32 develop adipokine profiles resembling those of obesity-induced metabolic changes

Cytokine (Philadelphia, Pa.), 2020-01, Vol.125, p.154793-154793, Article 154793

2020

Volltextzugriff (PDF)

A Sustained-Release Butyrate Tablet Suppresses Ex Vivo T Helper Cell Activation of Osteoarthritis Patients in a Double-Blind Placebo-Controlled Randomized Trial

Nutrients, 2024-10, Vol.16 (19), p.3384

2024

Volltextzugriff (PDF)

Publisher Correction: Cardiovascular effects of approved drugs for rheumatoid arthritis

Nature reviews. Rheumatology, 2021-05, Vol.17 (5), p.306-306

2021

Volltextzugriff (PDF)

High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study

Arthritis research & therapy, 2012-05, Vol.14 (3), p.R116-R116, Article R116

2012

Volltextzugriff (PDF)

Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients

Scientific reports, 2018-09, Vol.8 (1), p.14050-8, Article 14050

2018

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(60)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(53)
Life Sciences & Biomedicine
(40)
Humans
(38)
Rheumatoid Arthritis
(24)
Male
(23)
Female
(20)
Rheumatology
(20)
Middle Aged
(19)
Aged
(16)
Risk Factors
(14)
Adult
(13)
Cardiovascular Diseases
(12)
Patients
(10)
Arthritis, Rheumatoid - Blood
(9)
Inflammation
(9)
Arthritis, Rheumatoid - Complications
(8)
Arthritis, Rheumatoid - Drug Therapy
(8)
Atherosclerosis
(8)
Immunology
(8)
Technology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Cardiovascular effects of approved drugs for rheumatoid arthritis

Metabolic Induction of Trained Immunity through the Mevalonate Pathway

Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study

The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients

Rheumatoid Arthritis Disadvantages Younger Patients for Cardiovascular Diseases: A Meta-Analysis

Younger age and female gender are determinants of underestimated cardiovascular risk in rheumatoid arthritis patients: a prospective cohort study

Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial

Intramuscular methylprednisolone administration in hand osteoarthritis patients: a feasibility study to inform a randomized controlled trial

Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals

Cardiovascular risk management in rheumatoid arthritis: challenges ahead

Does Adding Single‐Nucleotide Polymorphisms to Risk Algorithms Improve Cardiovascular Disease Risk Prediction in Rheumatoid Arthritis? An Internal and External Validation of a Clinical Risk Score

Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events

Shared decision making in routine clinical care of patients with rheumatoid arthritis: an assessment of audio-recorded consultations

Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population

Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases

Association of Low-Dose Colchicine With Incidence of Knee and Hip Replacements : Exploratory Analyses From a Randomized, Controlled, Double-Blind Trial

The Use of Captopril in Rheumatoid Arthritis: Combining Treatment Targets

Interventions to support shared decision making for medication therapy in long term conditions: A systematic review

Diagnostic parameters of cellular tests for Lyme borreliosis in Europe (VICTORY study): a case-control study

Atherosclerosis in Rheumatoid Arthritis

Transgenic mice expressing human IL-32 develop adipokine profiles resembling those of obesity-induced metabolic changes

A Sustained-Release Butyrate Tablet Suppresses Ex Vivo T Helper Cell Activation of Osteoarthritis Patients in a Double-Blind Placebo-Controlled Randomized Trial

Publisher Correction: Cardiovascular effects of approved drugs for rheumatoid arthritis

High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study

Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients

Suchergebnisse filtern